A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.

BACKGROUND/AIM Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. This study intended to identify a biomarker panel to distinguish PCa from benign prostate using urine samples. MATERIALS AND METHODS We identified six biomarkers with differential gene expression in 154 PCa and benign prostate specimens. We then determined mRNA expression signature and the diagnostic performance of the 6-biomarker panel in 156 urine samples from patients with PCa and benign disease. RESULTS The 6-biomarker panel distinguished PCa from benign prostate cases with sensitivity of 80.6%, specificity of 62.9% and area under the curve (AUC) of 0.803 (p<0.0001), whereas serum PSA at 4 ng/ml cutoff had sensitivity of 95.5%, specificity of 20.2% and AUC of 0.521 (p<0.0001). CONCLUSION The 6-biomarker panel for use in urine samples was able to distinguish PCa from benign prostate with higher specificity and accuracy than PSA and may be useful in clinical settings.

[1]  B. Delahunt,et al.  Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure. , 2017, Anticancer research.

[2]  M. Schreckenberger,et al.  Diagnostic Performance of Multiparametric Magnetic Resonance Imaging and Fusion Targeted Biopsy to Detect Significant Prostate Cancer. , 2017, Anticancer research.

[3]  O. Ogunwobi,et al.  A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer. , 2017, RNA & disease.

[4]  Dong Wang,et al.  MYO6 knockdown inhibits the growth and induces the apoptosis of prostate cancer cells by decreasing the phosphorylation of ERK1/2 and PRAS40. , 2016, Oncology reports.

[5]  J. Persson,et al.  Use of two gene panels for prostate cancer diagnosis and patient risk stratification , 2016, Tumor Biology.

[6]  John T. Wei,et al.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. , 2015, The Journal of urology.

[7]  A. Goel,et al.  Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen. , 2011, Indian journal of pathology & microbiology.

[8]  T. D. de Reijke,et al.  Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. , 2011, The Journal of urology.

[9]  Paul McCullagh,et al.  Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer , 2010, BMC Cancer.

[10]  J. Bouchal,et al.  Urine markers in monitoring for prostate cancer , 2010, Prostate Cancer and Prostatic Diseases.

[11]  F. Schröder,et al.  PSA screening--a review of recent studies. , 2009, European journal of cancer.

[12]  Ralph Weissleder,et al.  Detection of early prostate cancer using a hepsin-targeted imaging agent. , 2008, Cancer research.

[13]  Jianjun Yu,et al.  A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. , 2008, Cancer research.

[14]  J. Witjes,et al.  Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.

[15]  K. Knudsen,et al.  Impact of differential cyclin D1 expression and localisation in prostate cancer , 2007, British Journal of Cancer.

[16]  Lei Wang,et al.  Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.

[17]  L. Marks,et al.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.

[18]  J. Richie,et al.  Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.